What's the vehicle anyhow?, page-21

Claims

1. A drug delivery system for topical administration of a therapeutic agent comprising the therapeutic agent lidocaine present in an amount of 4% by weight, propylene glycol in an amount between 2 and 6% by weight, oleyl alcohol in an amount between 2 and 6% by weight, and a volatile component comprising a volatile polydimethylsiloxane in an amount between 60 and 90% by weight.

2. The drug delivery system of claim 1, further comprising a thickener.

3. The drug delivery system of claim 2, wherein the drug delivery system comprises between 0.1 and 3.5 percent by weight of the thickener.

4. The drug delivery system of claim 2 or 3, wherein the thickener comprises hydroxypropylcellulose.

5. A method for administering the drug delivery system of claim 1 to an animal in need of such treatment, comprising applying an effective amount of the drug delivery system.

6. A method for the treatment or prophylaxis of a disease or condition in an animal comprising administering to a dermal surface of an animal in need of such treatment a therapeutically effective amount of a drug delivery system according to claim 1.

7. The method of claim 5 or 6, wherein the animal is a human.

8. The drug delivery system of claim 1, wherein the propylene glycol and oleyl alcohol are present in a ratio of 1:1.

9. The drug delivery system of claim 1, wherein the volatile component comprising a volatile polydimethylsiloxane is a linear or cyclic polydimethylsiloxane compound having a viscosity from about 0.5 to about 10 cst.

10. The drug delivery system of claim 9, wherein the linear polydimethylsiloxane is selected from the group consisting of hexamethyldisiloxane, decamethyltetrasiloxane, octamethyltrisiloxane, decamethylpentasiloxane and combinations thereof.

11. The drug delivery system of claim 10, wherein the linear polydimethylsiloxane is hexamethyldisiloxane.

12. The drug delivery system of claim 11, wherein the hexamethyldisiloxane has a viscosity of 0.65 cST.

13. The drug delivery system of claim 9, wherein the cyclic polydimethylsiloxane compound is a cyclomethicone.

14. The drug delivery system of claim 1, wherein the volatile component further comprises one or more short-chain alcohols.

15. The drug delivery system of claim 1, wherein the volatile component is present in an amount of between 60 and 85 percent by weight.

Patent History

Patent number: 9050293
Type: Grant
Filed: Jul 16, 2009
Date of Patent: Jun 9, 2015
Patent Publication Number: 20100016442
Assignee: Juventio, LLC (Chatham, NJ)
Inventors: David M. Cohen (Lauderdale By The Sea, FL), Eugene R. Cooper (Berwyn, PA)
Primary Examiner: Paul Zarek
Application Number: 12/503,929